The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial-Reference-Cited by-同舟云学术

The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial

Published:2020-08 Issue:2 Volume:78 Page:184-192
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Dearnaley David P.,Saltzstein Daniel R.,Sylvester John E.,Karsh Lawrence,Mehlhaff Bryan A.,Pieczonka Christopher^ORCID,Bailen James L.,Shi Hongliang^ORCID,Ye Zhan,Faessel Hélène M.,Lin Huamao,Zhu Yanyan,Saad Fred^ORCID,MacLean David B.,Shore Neal D.

Funder

Millennium Pharmaceuticals, Inc.

Myovant Sciences GmbH

NIHR Biomedical Research Centre

Publisher

Elsevier BV

Subject

Urology

Reference35 articles.

1. Systematic review of early vs deferred hormonal treatment of locally advanced prostate cancer: a meta-analysis of randomized controlled trials;Boustead;BJU Int,2007

2. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial;D’Amico;JAMA,2008

3. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial;Denham;Lancet Oncol,2005